Log in
RegisterGeneral remarks [RSABE / ABEL]
posted by Helmut 
– Vienna, Austria, 2015-02-02 15:06 (3753 d 21:36 ago) – Posting: # 14353
Views: 22,595
Hi nobody,
Scaling depends on the CVw of the reference. If you are able to manufacture a new product with smaller variability you get a reward in sample size (same widening of the AR but tighter CI). Example (T/R 0.9, 80% power, 4-period full replicate):
If you mean that the true CVwR is 25–28% and you observe 31%, yes. You scale the AR to 79.44–125.89% although the reference is not highly variable. Lucky punch for the producer, slightly increased risk for the patient.
❝ So: make your 25-28% something formulation…
Scaling depends on the CVw of the reference. If you are able to manufacture a new product with smaller variability you get a reward in sample size (same widening of the AR but tighter CI). Example (T/R 0.9, 80% power, 4-period full replicate):
CVwR CVwT n
0.35 0.35 34
0.35 0.25 26
❝ …go with 31% in the study and you are on the lucky side of life, hu?
If you mean that the true CVwR is 25–28% and you observe 31%, yes. You scale the AR to 79.44–125.89% although the reference is not highly variable. Lucky punch for the producer, slightly increased risk for the patient.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- EMA oracle Helmut 2015-01-27 16:27
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- EMA oracle nobody 2015-01-27 17:07
- Personal opinion ElMaestro 2015-01-27 17:56
- EMA oracle d_labes 2015-01-27 19:44
- EMA oracle nobody 2015-01-28 09:04
- EMA oracle ElMaestro 2015-01-28 13:11
- EMA oracle nobody 2015-01-28 09:04
- Response from Alfredo García-Arieta Helmut 2015-01-30 10:55
- Response from Alfredo García-Arieta nobody 2015-01-30 14:55
- Wonnemann’s Figure 4 on steroids Helmut 2015-02-01 01:35
- Wonnemann’s Figure 4 on steroids nobody 2015-02-01 11:18
- Wonnemann’s Figure 4 on steroids Helmut 2015-02-01 14:49
- General remarks ElMaestro 2015-02-01 18:43
- General remarks nobody 2015-02-01 22:04
- General remarks Helmut 2015-02-02 00:48
- General remarks nobody 2015-02-02 08:09
- General remarksHelmut 2015-02-02 14:06
- TIE: questions mittyri 2015-02-03 12:44
- TIE: questions Helmut 2015-02-03 13:24
- TIE: questions mittyri 2015-02-03 12:44
- General remarksHelmut 2015-02-02 14:06
- FDA RSABE & alpha inflation d_labes 2015-02-03 12:02
- FDA RSABE & alpha inflation Helmut 2015-02-03 12:22
- FDA RSABE & alpha inflation d_labes 2015-02-03 13:07
- FDA RSABE & alpha inflation Helmut 2015-02-03 13:41
- FDA RSABE & alpha inflation d_labes 2015-02-03 13:07
- FDA RSABE & alpha inflation Helmut 2015-02-03 12:22
- General remarks nobody 2015-02-02 08:09
- Wonnemann’s Figure 4 on steroids nobody 2015-02-01 11:18
- Wonnemann’s Figure 4 on steroids Helmut 2015-02-01 01:35
- Response from Alfredo García-Arieta nobody 2015-01-30 14:55
- New Zealand nobody 2015-01-31 11:25
- New Zealand Helmut 2015-02-01 16:08
- New Zealand nobody 2015-02-01 22:08
- New Zealand Helmut 2015-02-01 23:54
- New Zealand nobody 2015-02-02 08:07
- New Zealand Helmut 2015-02-01 23:54
- New Zealand nobody 2015-02-01 22:08
- New Zealand Helmut 2015-02-01 16:08
Ing. Helmut Schütz